Revance Therapeutics (RVNC) Competitors $4.17 -0.14 (-3.25%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RVNC vs. MRSN, HRTX, ARCT, GBIO, NGM, TVTX, PRAX, AVDL, GYRE, and SDGRShould you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Arcturus Therapeutics (ARCT), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Gyre Therapeutics (GYRE), and Schrödinger (SDGR). These companies are all part of the "medical" sector. Revance Therapeutics vs. Mersana Therapeutics Heron Therapeutics Arcturus Therapeutics Generation Bio NGM Biopharmaceuticals Travere Therapeutics Praxis Precision Medicines Avadel Pharmaceuticals Gyre Therapeutics Schrödinger Mersana Therapeutics (NASDAQ:MRSN) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Does the MarketBeat Community prefer MRSN or RVNC? Revance Therapeutics received 152 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.87% of users gave Mersana Therapeutics an outperform vote while only 62.07% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes24965.87% Underperform Votes12934.13% Revance TherapeuticsOutperform Votes40162.07% Underperform Votes24537.93% Which has preferable valuation and earnings, MRSN or RVNC? Mersana Therapeutics has higher earnings, but lower revenue than Revance Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$36.85M7.41-$171.67M-$0.61-3.62Revance Therapeutics$234.04M1.87-$323.99M-$1.93-2.16 Is MRSN or RVNC more profitable? Revance Therapeutics has a net margin of -74.67% compared to Mersana Therapeutics' net margin of -214.20%. Revance Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% Revance Therapeutics -74.67%N/A -37.22% Do institutionals and insiders hold more shares of MRSN or RVNC? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are owned by institutional investors. 11.8% of Mersana Therapeutics shares are owned by insiders. Comparatively, 5.1% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, MRSN or RVNC? Mersana Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Does the media prefer MRSN or RVNC? In the previous week, Mersana Therapeutics had 9 more articles in the media than Revance Therapeutics. MarketBeat recorded 17 mentions for Mersana Therapeutics and 8 mentions for Revance Therapeutics. Mersana Therapeutics' average media sentiment score of 0.42 beat Revance Therapeutics' score of -0.09 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mersana Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revance Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer MRSN or RVNC? Mersana Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 171.49%. Revance Therapeutics has a consensus target price of $9.66, suggesting a potential upside of 131.59%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Mersana Therapeutics is more favorable than Revance Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Revance Therapeutics 0 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.11 SummaryMersana Therapeutics beats Revance Therapeutics on 12 of the 19 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVNC vs. The Competition Export to ExcelMetricRevance TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$437.44M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-2.164.7865.5913.48Price / Sales1.87377.381,278.7587.67Price / CashN/A51.2039.7035.24Price / Book-2.699.686.475.93Net Income-$323.99M$154.43M$119.73M$225.73M7 Day Performance12.70%-9.46%-5.13%-1.34%1 Month Performance-19.50%-7.27%-2.71%1.15%1 Year Performance-42.64%28.13%31.08%24.02% Revance Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVNCRevance Therapeutics3.8687 of 5 stars$4.17-3.2%$9.66+131.6%-39.7%$437.44M$234.04M-2.16597MRSNMersana Therapeutics4.3148 of 5 stars$2.59+0.8%N/A+43.5%$317.74M$36.85M-2.98150Analyst ForecastAnalyst RevisionNews CoverageGap UpHRTXHeron Therapeutics4.0402 of 5 stars$1.78+1.8%N/A+29.8%$270.09M$127.04M-5.57300Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageARCTArcturus Therapeutics2.514 of 5 stars$20.55+4.7%N/A-27.8%$553.41M$169.93M-8.00180Gap UpGBIOGeneration Bio3.5391 of 5 stars$2.32+2.7%N/A+37.5%$154.95M$5.90M-1.06150Gap UpNGMNGM Biopharmaceuticals3.5585 of 5 stars$1.54-1.3%N/A+155.2%$128.53M$4.42M-0.90138TVTXTravere Therapeutics3.1218 of 5 stars$19.83-0.1%N/A+194.8%$1.55B$203.45M-4.36460Analyst ForecastPRAXPraxis Precision Medicines1.7896 of 5 stars$82.77+6.3%N/A+398.0%$1.54B$1.61M-8.04110Insider SellingNews CoverageAVDLAvadel Pharmaceuticals2.6305 of 5 stars$15.94flatN/A+1.8%$1.53B$27.96M-13.62154Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownGYREGyre Therapeutics0.5578 of 5 stars$15.76+2.9%N/A+1.2%$1.47B$113.45M0.0040Short Interest ↓News CoverageSDGRSchrödinger2.0565 of 5 stars$19.50+4.0%N/A-40.0%$1.42B$216.67M-7.28867Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies MRSN Competitors HRTX Competitors ARCT Competitors GBIO Competitors NGM Competitors TVTX Competitors PRAX Competitors AVDL Competitors GYRE Competitors SDGR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RVNC) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
